KRYS
Krystal Biotech, Inc. · Healthcare · Market cap $9.5B
Insiders sold $26.5M net in the last 90 days ·4 sellers, 0 buyers· 3 of 4 sales under Rule 10b5-1 plans· latest Form 4 filed Sep 4, 2026
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$105.3M
reported sales (SEC code S)
Unique Insiders
6
in the rolling window
Latest filing
Sep 4, 2026
Krishnan Suma
Krystal Biotech, Inc. (KRYS) has 18 SEC Form 4 filings (174 transaction rows) in the rolling window, disclosed by 6 distinct insiders. Most recent filing: Sep 4, 2026.
Inside the rolling window, 6 insiders at Krystal Biotech, Inc. reported no open-market purchases and 18 open-market sales totaling $105.3M. The most active filer is President, R&D Krishnan Suma with 4 filings. Insiders have net sold $42.1M over the trailing 6 months. The most recent open-market filing is a sale of 25,000 shares by President, R&D Krishnan Suma, dated Sep 4, 2026, worth $9.0M.
- Industry:Biotechnology
- CEO:Krish S. Krishnan
- Employees:295
- HQ:Pittsburgh, PA, US
- IPO:2017-09-20
| Source | |||||||
|---|---|---|---|---|---|---|---|
Krishnan SumaFirst in 3 months | President, R&D | Sale | 25,000 | $9.0M | Sep 4 | -10.1% | SEC ↗ |
Krishnan Krish SFirst in 3 months | President and CEO | Sale | 25,000 | $9.0M | Sep 4 | — | SEC ↗ |
ROSSI DINO AFirst in 6 months | Director | Sale | 25,000 | $8.2M | Aug 14 | — | SEC ↗ |
| EVP, General Counsel | Sale | 1,000 | $347K | Jun 26 | — | SEC ↗ | |
Krishnan SumaFirst in 3 months | President, R&D | Sale | 25,000 | $7.7M | Jun 5 | — | SEC ↗ |
Krishnan Krish SFirst in 3 months | President and CEO | Sale | 25,000 | $7.7M | Jun 5 | — | SEC ↗ |
Thomas John CharlesFirst filing | EVP, General Counsel | Sale | 642 | $194K | May 27 | — | SEC ↗ |
Krishnan Krish SFirst in 3 months | President and CEO | Sale | 25,000 | $6.6M | Mar 6 | — | SEC ↗ |
Krishnan SumaFirst in 3 months | President, R&D | Sale | 25,000 | $6.6M | Mar 6 | — | SEC ↗ |
| Chief Accounting Officer | Sale | 750 | $201K | Mar 3 | — | SEC ↗ | |
| Director | Sale | 11,803 | $3.3M | Mar 3 | — | SEC ↗ | |
JANNEY DANIELFirst filing | Director | Sale | 51,720 | $13.8M | Feb 26 | — | SEC ↗ |
JANNEY DANIELFirst filing | Director | Sale | 700 | $193K | Feb 26 | — | SEC ↗ |
JANNEY DANIELFirst filing | Director | Sale | 7,741 | $2.1M | Feb 26 | — | SEC ↗ |
ROSSI DINO AFirst filing | Director | Sale | 18,950 | $5.0M | Feb 23 | — | SEC ↗ |
ROMANO KATHRYNFirst filing | Chief Accounting Officer | Sale | 12,500 | $3.4M | Feb 11 | — | SEC ↗ |
Krishnan Krish SFirst filing | President and CEO | Sale | 50,000 | $11.0M | Dec 5 | — | SEC ↗ |
Krishnan SumaFirst filing | President, R&D | Sale | 50,000 | $11.0M | Dec 5 | — | SEC ↗ |
Earnings: last 7 quarters
Congress trading KRYS 1 all-time
- RRep. Chris JacobsPurchase$1,001 - $15,0002022-12-12
STOCK Act disclosures are filed up to 45 days after the trade. Amount is a disclosed range, not an exact figure.
Frequently asked questions
How many SEC Form 4 insider filings does KRYS have?
Krystal Biotech, Inc. (KRYS) has 18 SEC Form 4 filings (174 transaction rows) in the rolling 365-day window, disclosed by 6 distinct insiders. Most recent filing: Sep 4, 2026.
When was the most recent SEC Form 4 filing for KRYS?
The most recent Form 4 filing for KRYS on Tracefour is dated Sep 4, 2026.
Who is the most active insider at KRYS?
The most active SEC Form 4 filer at KRYS in the rolling window is President, R&D Krishnan Suma, with 4 filings.
What is the net insider flow at KRYS over the last 6 months?
Over the trailing 180 days, insiders at KRYS have net sold $42.1M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at KRYS in the current window?
Inside the rolling window, insiders at KRYS bought $0 and sold $105.3M based on SEC Form 4 filings.
Can I get alerts for KRYS insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Krystal Biotech, Inc. (KRYS). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Krystal Biotech, Inc. is in the Healthcare sector.